0000000000055531

AUTHOR

Eberhard Rabe

showing 4 related works from this author

Minimally invasive techniques in the treatment of saphenous varicose veins.

2008

Lower extremity venous insufficiency is common and increases with age. In addition to classical symptoms, it may result in skin changes and venous ulcers. Chronic venous insufficiency has a great impact on patients' health-related quality of life and is associated with considerable health care costs. Surgical ligation Of the junction with or without stripping has been the standard of care in the treatment of insufficient great and small saphenous veins. However, the recurrence rates are relatively high and surgery may be associated with serious adverse events and considerable down time; it is also cosmetically Suboptimal. To improve efficacy, patients' health-related quality of life and tre…

medicine.medical_specialtymedicine.drug_classChronic venous insufficiencyRadiofrequency ablationmedicine.medical_treatmentLow molecular weight heparinDermatologylaw.inventionVaricose VeinsQuality of lifelawVaricose veinsSclerotherapymedicineSclerotherapyHumansMinimally Invasive Surgical ProceduresSaphenous VeinAdverse effectbusiness.industryGreat saphenous veinmedicine.diseaseSurgeryCatheter AblationLaser Therapymedicine.symptombusinessJournal of the American Academy of Dermatology
researchProduct

Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised…

2017

Summary Background Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism. Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compared with fondaparinux because it does not require daily subcutaneous injection and is cheaper. We compared efficacy outcomes in patients with superficial-vein thrombosis and additional risk factors given either rivaroxaban or fondaparinux to assess whether rivaroxaban is non-inferior to fondaparinux in the prevention of thromboembolic complications. Methods In this open-label, masked endpoint, randomised, non-inferiority phase 3b trial, we recruited patients aged 18 years or older with symptomatic superficial-vein thr…

medicine.medical_specialtyeducation.field_of_studyRivaroxabanSuperficial vein thrombosisbusiness.industryPopulationHematology030204 cardiovascular system & hematologyFondaparinuxmedicine.diseaseThrombosislaw.inventionSurgeryPulmonary embolism03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineThrombusbusinesseducationmedicine.drugThe Lancet Haematology
researchProduct

Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply

2017

medicine.medical_specialtySuperficial vein thrombosisbusiness.industryMEDLINEHematology030204 cardiovascular system & hematologymedicine.diseaseThrombosisSurgery03 medical and health sciencesVenous thrombosis0302 clinical medicinemedicine030212 general & internal medicinebusinessThe Lancet Haematology
researchProduct

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).

2021

Objective Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions. Methods Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding. Results A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was …

AdultMalemedicine.medical_specialtySuperficial vein thrombosismedicine.drug_classDeep veinLow molecular weight heparinHemorrhage030204 cardiovascular system & hematology030230 surgeryFondaparinuxVaricose Veins03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsmedicineHumansProspective StudiesAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioLeg UlcerAnticoagulantsHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeFondaparinuxLower ExtremityVenous InsufficiencySurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismStockings Compressionmedicine.drugFactor Xa InhibitorsEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
researchProduct